Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Rawan Faramand, MD
Moffitt Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Moffitt Cancer Center
Tampa, Florida, United States
Aleksandr Lazaryan, MDAsmita Mishra, MDBijal Shah, MDCiara Freeman, MDDoris Hansen, MDFabiana Perna, MDFarhad Khimani, MDFrederick Locke, MDHien Liu, MDJoseph Pidala, MDLia Perez, MDMelissa Alsina, MDMichael Jain, MDNancy Torres Luna, MDNelli Bejanyan, MDOmar Castaneda Puglianini, MDRawan Faramand, MDReshma Ramlal, MDSayeef Mirza, MDTaiga Nishihori, MDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 21 Jan 2026
- Primary completion
- 30 Nov 2029
- Completion
- 30 Nov 2029
- Last update posted
- 27 Mar 2026
- Registered enrollment
- 36
- Registry id
- NCT07250087
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.